-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78

Benzinga·08/12/2026 12:33:55
Listen to the news
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $80 to $78.